Literature DB >> 17060851

Matching of the minor histocompatibility antigen HLA-A1/H-Y may improve prognosis in corneal transplantation.

Daniel Böhringer1, Eric Spierings, Jürgen Enczmann, Stefan Böhringer, Rainer Sundmacher, Els Goulmy, Thomas Reinhard.   

Abstract

BACKGROUND: Minor histocompatibility (H) antigens are peptides of allelic intracellular proteins that play an important role in human leukocyte antigen (HLA) matched transplantations. In an animal model of keratoplasty, minor H antigens have even been reported to exceed the immunogenicity of major H antigens (MHC). This investigation is to assess any benefit of matching the broadly expressed gender (H-Y) and HA-3 antigens in HLA-A1 donor positive human keratoplasty.
METHODS: A total of 229 HLA-A1 donor positive keratoplasties were analyzed. A Cox proportional hazards model and Kaplan-Meier analysis were applied to estimate the effect of H-Y or HA-3 mismatches on rejection-free graft survival.
RESULTS: Eighty-one cases were mismatched for H-Y (male donor to female recipient). A mean follow up of two years showed graft survival as high as 88% in the H-Y compatible group compared to only 77% in the H-Y mismatched group (P = 0.02). Eight out of 62 cases were mismatched for HA-3. No statistically significant influence of HA-3 matching on rejection-free graft survival was observed (85% vs. 73%, P=0.52).
CONCLUSION: HLA-A1/H-Y matching and matching for other broadly expressed minor H antigens may further improve prognosis in keratoplasty.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17060851     DOI: 10.1097/01.tp.0000235908.54766.44

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  16 in total

1.  Rejection Prophylaxis in Corneal Transplant.

Authors:  Daniel Böhringer; Birgit Grotejohann; Gabriele Ihorst; Helga Reinshagen; Eric Spierings; Thomas Reinhard
Journal:  Dtsch Arztebl Int       Date:  2018-04-13       Impact factor: 5.594

2.  [Matching minor transplantation antigens in penetrating keratoplasty].

Authors:  E Spierings; T Reinhard; E Goulmy; D Böhringer
Journal:  Ophthalmologe       Date:  2007-03       Impact factor: 1.059

Review 3.  High-risk corneal allografts: A therapeutic challenge.

Authors:  Tian Yu; Vijayalakshmi Rajendran; May Griffith; John V Forrester; Lucia Kuffová
Journal:  World J Transplant       Date:  2016-03-24

4.  Donor-recipient gender and size mismatch affects graft success after kidney transplantation.

Authors:  Jennifer McGee; Jeanette H Magnus; Tareq M Islam; Bernard M Jaffe; Rubin Zhang; Sander S Florman; L Lee Hamm; Navyata Mruthinti; Karen Sullivan; Douglas P Slakey
Journal:  J Am Coll Surg       Date:  2010-05       Impact factor: 6.113

Review 5.  Alloimmunity and Tolerance in Corneal Transplantation.

Authors:  Afsaneh Amouzegar; Sunil K Chauhan; Reza Dana
Journal:  J Immunol       Date:  2016-05-15       Impact factor: 5.422

Review 6.  Corneal transparency: genesis, maintenance and dysfunction.

Authors:  Yureeda Qazi; Gilbert Wong; Bryan Monson; Jack Stringham; Balamurali K Ambati
Journal:  Brain Res Bull       Date:  2009-05-27       Impact factor: 4.077

Review 7.  [Human leukocyte antigen (HLA) system in ophthalmology].

Authors:  T Lapp; D Reinhold; D Böhringer; T Reinhard
Journal:  Ophthalmologe       Date:  2013-09       Impact factor: 1.059

8.  H-Y incompatibility predicts short-term outcomes for kidney transplant recipients.

Authors:  S Joseph Kim; John S Gill
Journal:  J Am Soc Nephrol       Date:  2009-06-18       Impact factor: 10.121

9.  Correlation of Chimerism with Acute Graft-versus-Host Disease in Rats following Liver Transplantation.

Authors:  Fei Xue; Wei Chen; Xue-Li Bai; Guo-Dong Xu; Liang Liang; Ting-Bo Liang
Journal:  Int J Hepatol       Date:  2011-05-17

10.  The effect of in vivo grown corneal epithelium transplantation on persistent epithelial defects with limbal stem cell deficiency.

Authors:  Jee Taek Kim; Yeoun Sook Chun; Kye Yong Song; Geo Young Song; Jae Chan Kim
Journal:  J Korean Med Sci       Date:  2008-06       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.